A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Clinical trial NCT05688839 · UNKNOWN

Trial details

NCT number: NCT05688839
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Novel COVID-19-Infected Pneumonia

Start date: 2024-04-01
Primary completion: 2025-02-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.